StockData

Keros Therapeutics vs Roivant Sciences

KROS and ROIV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KROS and ROIV compare

Roivant Sciences is the larger company, worth 125 times as much as Keros Therapeutics ($28.0B against $224M).

Roivant Sciences grew revenue faster over the last twelve months (−67.6% versus −93.7% for Keros Therapeutics).

Keros Therapeutics keeps more of each dollar of sales as profit, with a net margin of −572% compared with −3535% at Roivant Sciences.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKROSROIV
Size and price
Market cap$224M$28.0B
Share price$11.31$38.71
Change, 1 year−34.5%90.8%
Change, 5 years−79.8%453%
Beta (5Y)2.040.42
Employees78721
StockData Score
Total score77
Valuation score1 (better)0
Growth score00
Performance score11
Health score56 (better)
Dividend score00
Valuation
P/S15.4× (better)3712×
P/B0.9× (better)6.6×
FCF yield−21.6%−2.9% (better)
Growth
Revenue growth (TTM)−93.7%−67.6% (better)
Revenue growth, 5Y average–−19.1%
Net income growth (TTM)−543%–
EPS growth (TTM)−1287%–
Profitability
Operating margin−698% (better)−7915%
Net margin−572% (better)−3535%
FCF margin−334% (better)−10901%
Return on equity−17.2%−6.2% (better)
Return on invested capital−755%−407% (better)
Financial health
Debt / equity0.000.00
Current ratio21.96 (better)16.72
Altman Z-score2.6744.02 (better)
Piotroski F-score6 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions101%78.1%
Held by insiders53.3%13.9%
Insider net buying, 12 months−$453K (better)−$798M
Superinvestors holding–1
Short interest, % of float11.7%7.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.